CN101195638A - Trinuclear phosphamide ester compounds containing tegafur and aza-silicon - Google Patents
Trinuclear phosphamide ester compounds containing tegafur and aza-silicon Download PDFInfo
- Publication number
- CN101195638A CN101195638A CNA2007101922872A CN200710192287A CN101195638A CN 101195638 A CN101195638 A CN 101195638A CN A2007101922872 A CNA2007101922872 A CN A2007101922872A CN 200710192287 A CN200710192287 A CN 200710192287A CN 101195638 A CN101195638 A CN 101195638A
- Authority
- CN
- China
- Prior art keywords
- reaction
- tegafur
- silicon
- toluene
- mixed solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation method of phosphoramidate compound, which comprises materials and a three-necked bottle. The invention uses alkoxy (or phenoxy) phosphorodichloridate as material to be reacted with N3-hydroxyethyl tegafur and aminopropyl nitrogen heterocyclic tricyclic silicon, to synthesize the compound containing tegafur and nitrogen heterocyclic tricyclic silicon. According to the activity splice theory of drug synthesis, the compound has a little toxic and side effects, persistent efficacy, simple synthesis method, low cost, industrialization suitability and the ability for treating colon cancer and gastric cancer, as one anti-tumor agent.
Description
Technical field
The present invention relates to a kind of preparation method of industrial chemicals, especially a kind of preparation method of phosphoramidate compound.
Background technology
N
1-2-furyl-5-fluor-uracil is a kind of antimetabolite that stops tumour cell miazines Nucleotide to form, be used for the treatment of the rectum cancer, colorectal carcinoma and cancer of the stomach etc., owing to have bone marrow depression and gastrointestinal side effect, toxic side effect is big, and its application has been subjected to certain restriction.
Summary of the invention
The present invention is directed to the defective of prior art, a kind of preparation method of phosphoramidate compound is provided.
To achieve these goals, the present invention takes following measure to realize:
A kind of preparation method of phosphoramidate compound comprises raw material, three-necked bottle, it is characterized in that with alkoxyl group (or phenoxy group) phosphinylidyne dichloro be raw material successively with N
3-hydroxyethyl Tegafur, the reaction of aminopropyl azepine silicon tricyclic, synthetic Tegafur, the aza-silicon tricyclic compound of containing simultaneously.
The present invention has following effect with respect to prior art: the present invention is according to the active superposition theorem of medicine synthetic, and synthetic compound toxic side effect is little, and lasting medicine, simple synthetic method are easily gone, and is expensive few, is suitable for industrialization.
Embodiment
The mixed solution of 0.82g oxyethyl group phosphinylidyne dichloro and 10mL toluene is placed the 50mL three-necked bottle, ice bath drips the mixed solution that 1.22gN3-hydroxyethyl Tegafur is dissolved in 15mL toluene and 0.8mL triethylamine down, stir, produce a large amount of white cigarettes immediately, keep producing white solid behind 0 ℃ of reaction 1h, rise to room temperature continuation reaction 2h after-filtration and remove the triethylamine salt of generation, filtrate changes constant pressure funnel over to, splash into 1.16g aminopropyl azepine silicon tricyclic under the room temperature and be dissolved in the mixed solution of 10mL toluene and 0.8mL triethylamine, stir, have white cigarette to generate, be warming up to behind the reaction 2h and continue reaction 1h about 50 ℃, the thin-layer chromatography monitoring reaction finishes, and produces a large amount of white solids, cooled and filtered, use a small amount of washing, remove the triethylamine salt of generation, get white solid after the drying, use the dehydrated alcohol recrystallization.
In the reality, the present invention is used for the treatment of colorectal carcinoma and cancer of the stomach etc., it is a kind of anti-tumor drug, has wide biological activity, the azepine silicon tricyclic that contains hydrocarbyl amino has the activity of stronger inhibition tumour, because its mode of action is different fully with common medicine, can bring into play synergy when particularly using simultaneously with general chemicals, its drug effect is stronger more lasting, therefore is considered to the medicine that a class has DEVELOPMENT PROSPECT very much.
Claims (2)
1. the preparation method of a phosphoramidate compound comprises raw material, three-necked bottle, it is characterized in that with alkoxyl group (or phenoxy group) phosphinylidyne dichloro be raw material successively with N
3-hydroxyethyl Tegafur, the reaction of aminopropyl azepine silicon tricyclic, synthetic Tegafur, the aza-silicon tricyclic compound of containing simultaneously.
2. according to claim 1, it is characterized in that the mixed solution of 0.82g oxyethyl group phosphinylidyne dichloro and 10mL toluene is placed the 50mL three-necked bottle, ice bath drips the mixed solution that 1.22gN3-hydroxyethyl Tegafur is dissolved in 15mL toluene and 0.8mL triethylamine down, stir, produce a large amount of white cigarettes immediately, keep producing white solid behind 0 ℃ of reaction 1h, rise to room temperature continuation reaction 2h after-filtration and remove the triethylamine salt of generation, filtrate changes constant pressure funnel over to, splashes into the mixed solution that 1.16g aminopropyl azepine silicon tricyclic is dissolved in 10mL toluene and 0.8mL triethylamine under the room temperature, stir, have white cigarette to generate, be warming up to behind the reaction 2h and continue reaction 1h about 50 ℃, the thin-layer chromatography monitoring reaction finishes, produce a large amount of white solids, cooled and filtered with washing on a small quantity, is removed the triethylamine salt of generation, get white solid after the drying, use the dehydrated alcohol recrystallization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101922872A CN101195638A (en) | 2007-12-24 | 2007-12-24 | Trinuclear phosphamide ester compounds containing tegafur and aza-silicon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101922872A CN101195638A (en) | 2007-12-24 | 2007-12-24 | Trinuclear phosphamide ester compounds containing tegafur and aza-silicon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101195638A true CN101195638A (en) | 2008-06-11 |
Family
ID=39546281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101922872A Pending CN101195638A (en) | 2007-12-24 | 2007-12-24 | Trinuclear phosphamide ester compounds containing tegafur and aza-silicon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101195638A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176084A1 (en) * | 2012-05-22 | 2013-11-28 | 日産化学工業株式会社 | Silane coupling agent containing silylalkyl phosphoramidate compound |
-
2007
- 2007-12-24 CN CNA2007101922872A patent/CN101195638A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176084A1 (en) * | 2012-05-22 | 2013-11-28 | 日産化学工業株式会社 | Silane coupling agent containing silylalkyl phosphoramidate compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101580477B (en) | Dehydroabietylamine derivatives and application thereof in bactericidal and antineoplastic medicaments | |
| TR201807101T4 (en) | Imidazo [4,5-c] quinolin-2-one compounds and their use in the treatment of cancer. | |
| Joseyphus et al. | Synthesis and characterization of metal complexes of Schiff base ligand derived from imidazole-2-carboxaldehyde and 4-aminoantipyrine | |
| Bartholomä et al. | Synthesis, cytotoxicity, and insight into the mode of action of Re (CO) 3 thymidine complexes | |
| TWI762743B (en) | Sulfonamide compounds and use thereof | |
| US8183247B2 (en) | Boron compounds useful in BNCT | |
| CA3110402A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| WO2019144885A1 (en) | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound | |
| CN106632379B (en) | A kind of Bergenin azepine cinnamate derivative compound and its synthetic method having anti-tumor activity | |
| CN102924507A (en) | An anti-tumor compound and its preparation method, application, and pharmaceutical compositions | |
| JP2018535229A (en) | Substituted triazolopiperazine PARP inhibitors, production method thereof and uses | |
| Gholivand et al. | Synthesis, characterization, cytotoxicity studies, theoretical approach of adsorptive removal and molecular calculations of four new phosphoramide derivatives and related graphene oxide | |
| CN101195638A (en) | Trinuclear phosphamide ester compounds containing tegafur and aza-silicon | |
| CN107226826A (en) | Tenofovir Chinese mugwort draws phenol amine fumarate compound and its pharmaceutical composition | |
| CN102827116B (en) | Alpha-aryl-gamma-methylene butene lactone compounds, and synthesis method and application thereof | |
| Jabbar | Synthesis, characterization and antibacterial activity of carbamate derivatives of isatin | |
| TW202104218A (en) | Chiral indole compounds and their use | |
| CN103626845B (en) | As the aryl of glycogen phosphorylase inhibitors and pyrroles-2-methane amide dipeptidase derivant, its preparation method and medicinal use | |
| CN106831474B (en) | One kind-the α containing alpha-aromatic, β-diamino acid ester derivant and its synthetic method and application | |
| CN100556460C (en) | Grafted nano carbon anticancer prodrug and its production and application | |
| CN102010348A (en) | Salicylamide ester type derivative and preparation method and application thereof | |
| CN107936061B (en) | A kind of synthetic method of cyclophosphamide | |
| CN102702297B (en) | Preparation method of cholic acid-naphthalimide compound | |
| CN113453672A (en) | Cancer cell proliferation inhibitory composition and processed food | |
| Chetana et al. | Novel ligand 1-benzyl-3-(4-ethyl-pyridin-2-Yl)-thiourea and Cu (I) complexes: DNA interaction, antibacterial and thermal studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080611 |